Loading
A phase 1/2 trial of DM002 in ovarian cancer, prostate cancer, endometrial cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Xadcera Biopharmaceutical (Suzhou) Co., Ltd., now recruiting.
A Study of DM002 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06751329 by Xadcera Biopharmaceutical (Suzhou) Co., Ltd., with 280 participants planned, started 2025-02-17 and due to reach its primary completion in 2027-10-08. Interventions recorded: DM002.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/